1. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77-93. PMID:
19945913.
2. Elbrink J, Malhotra SK. The pathogenesis of Duchenne muscular dystrophy: significance of experimental observations. Med Hypotheses 1985;17:375-385. PMID:
4046906.
3. Deconinck N, Dan B. Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr Neurol 2007;36:1-7. PMID:
17162189.
4. Hoogerwaard EM, Bakker E, Ippel PF, Oosterwijk JC, Majoor-Krakauer DF, Leschot NJ, Van Essen AJ, Brunner HG, van der Wouw PA, Wilde AA, et al. Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. Lancet 1999;353:2116-2119. PMID:
10382696.
5. Moon JH, Park YG, Park JS, Na YM, Kim YJ, Kang SW. Clinical profile of Duchenne muscular dystrophy. J Korean Acad Rehabil Med 2001;25:241-248.
6. Madorsky JG, Radford LM, Neumann EM. Psychosocial aspects of death and dying in Duchenne muscular dystrophy. Arch Phys Med Rehabil 1984;65:79-82. PMID:
6696607.
7. Karol LA. Scoliosis in patients with Duchenne muscular dystrophy. J Bone Joint Surg Am 2007;89(Suppl 1): 155-162. PMID:
17272432.
8. Sasaki K, Sakata K, Kachi E, Hirata S, Ishihara T, Ishikawa K. Sequential changes in cardiac structure and function in patients with Duchenne type muscular dystrophy: a two-dimensional echocardiographic study. Am Heart J 1998;135:937-944. PMID:
9630096.
9. Romfh A, McNally EM. Cardiac assessment in Duchenne and Becker muscular dystrophies. Curr Heart Fail Rep 2010;7:212-218. PMID:
20857240.
10. Muntoni F. Cardiomyopathy in muscular dystrophies. Curr Opin Neurol 2003;16:577-583. PMID:
14501841.
11. Finsterer J. Cardiopulmonary support in Duchenne muscular dystrophy. Lung 2006;184:205-215. PMID:
17006747.
12. Houde S, Filiatrault M, Fournier A, Dube J, D'Arcy S, Berube D, Brousseau Y, Lapierre G, Vanasse M. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 2008;38:200-206. PMID:
18279756.
13. Angelini C, Pegoraro E, Turella E, Intino MT, Pini A, Costa C. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve 1994;17:386-391. PMID:
8170484.
14. Eagle M. Report on the muscular dystrophy campaign workshop: exercise in neuromuscular diseases Newcastle, January 2002. Neuromuscul Disord 2002;12:975-983. PMID:
12467755.
15. Bach JR, Martinez D, Saulat B. Duchenne muscular dystrophy: the effect of glucocorticoids on ventilator use and ambulation. Am J Phys Med Rehabil 2010;89:620-624. PMID:
20647779.
16. Guglieri M, Bushby K. Molecular treatments in Duchenne muscular dystrophy. Curr Opin Pharmacol 2010;10:331-337. PMID:
20434401.
18. Nelson SF, Crosbie RH, Miceli MC, Spencer MJ. Emerging genetic therapies to treat Duchenne muscular dystrophy. Curr Opin Neurol 2009;22:532-538. PMID:
19745732.
19. Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve 1981;4:186-197. PMID:
7017401.
20. Lue YJ, Su CY, Yang RC, Su WL, Lu YM, Lin RF, Chen SS. Development and validation of a muscular dystrophy-specific functional rating scale. Clin Rehabil 2006;20:804-817. PMID:
17005504.
21. Bakker JP, De Groot IJ, Beelen A, Lankhorst GJ. Predictive factors of cessation of ambulation in patients with Duchenne muscular dystrophy. Am J Phys Med Rehabil 2002;81:906-912. PMID:
12447089.
22. Main M, Mercuri E, Haliloglu G, Baker R, Kinali M, Muntoni F. Serial casting of the ankles in Duchenne muscular dystrophy: can it be an alternative to surgery? Neuromuscul Disord 2007;17:227-230. PMID:
17303425.
23. Rose KJ, Burns J, Wheeler DM, North KN. Interventions for increasing ankle range of motion in patients with neuromuscular disease. Cochrane Database Syst Rev 2010;2:CD006973PMID:
20166090.
24. Parreira SL, Resende MB, Della Corte Peduto M, Marie SK, Carvalho MS, Reed UC. Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy. Arq Neuropsiquiatr 2007;65:245-250. PMID:
17607422.
25. Palmieri B, Sblendorio V, Ferrari A, Pietrobelli A. Duchenne muscle activity evaluation and muscle func tion preservation: is it possible a prophylactic strategy? Obes Rev 2008;9:121-139. PMID:
18034791.
26. Heller KD, Wirtz DC, Siebert CH, Forst R. Spinal stabilization in Duchenne muscular dystrophy: principles of treatment and record of 31 operative treated cases. J Pediatr Orthop B 2001;10:18-24. PMID:
11269806.
27. Cheuk DK, Wong V, Wraige E, Baxter P, Cole A, N'Diaye T, Mayowe V. Surgery for scoliosis in Duchenne muscular dystrophy. Cochrane Database Syst Rev 2007;1:CD005375PMID:
17253553.
28. Kinali M, Messina S, Mercuri E, Lehovsky J, Edge G, Manzur AY, Muntoni F. Management of scoliosis in Duchenne muscular dystrophy: a large 10-year retrospective study. Dev Med Child Neurol 2006;48:513-518. PMID:
16700946.
29. Matecki S, Topin N, Hayot M, Rivier F, Echenne B, Prefaut C, Ramonatxo M. A standardized method for the evaluation of respiratory muscle endurance in patients with Duchenne muscular dystrophy. Neuromuscul Disord 2001;11:171-177. PMID:
11257474.
30. Phillips MF, Quinlivan RC, Edwards RH, Calverley PM. Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med 2001;164:2191-2194. PMID:
11751186.
31. Corrado G, Lissoni A, Beretta S, Terenghi L, Tadeo G, Foglia-Manzillo G, Tagliagambe LM, Spata M, Santarone M. Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy. Am J Cardiol 2002;89:838-841. PMID:
11909570.
32. Mohyuddin T, Jacobs IB, Bahler RC. B-type natriuretic peptide and cardiac dysfunction in Duchenne muscular dystrophy. Int J Cardiol 2007;119:389-391. PMID:
17079036.
33. Beggs AH, Koenig M, Boyce FM, Kunkel LM. Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction. Hum Genet 1990;86:45-48. PMID:
2253937.
34. Sellner LN, Taylor GR. MLPA and MAPH: new techniques for detection of gene deletions. Hum Mutat 2004;23:413-419. PMID:
15108271.
35. Nicholson LV, Johnson MA, Bushby KM, Gardner-Medwin D, Curtis A, Ginjaar IB, den Dunnen JT, Welch JL, Butler TJ, Bakker E, et al. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 2. Correlations within individual patients. J Med Genet 1993;30:737-744. PMID:
8411068.
36. Den Dunnen JT, Grootscholten PM, Bakker E, Blonden LA, Ginjaar HB, Wapenaar MC, van Paassen HM, van Broeckhoven C, Pearson PL, van Ommen GJ. Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. Am J Hum Genet 1989;45:835-847. PMID:
2573997.
37. Roberts RG, Bobrow M, Bentley DR. Point mutations in the dystrophin gene. Proc Natl Acad Sci U S A 1992;89:2331-2335. PMID:
1549596.
38. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987;50:509-517. PMID:
3607877.
39. Forrest SM, Cross GS, Flint T, Speer A, Robson KJ, Davies KE. Further studies of gene deletions that cause Duchenne and Becker muscular dystrophies. Genomics 1988;2:109-114. PMID:
3410474.
40. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988;2:90-95. PMID:
3384440.
41. Cho H, Hong JM, Lee KA, Choi YC. Clinical usefulness of molecular diagnosis in dystrophin gene mutations using the multiplex ligation-dependent probe amplification (MLPA) method. J Korean Neurol Assoc 2010;28:22-26.